Article Text

other Versions

PDF
Letter
Increased κ-opioid receptor expression and function during chronic visceral hypersensitivity
  1. Patrick A Hughes1,2,
  2. Joel Castro1,2,
  3. Andrea M Harrington1,2,
  4. Nicole Isaacs1,
  5. Melissa Moretta1,
  6. Gareth A Hicks3,
  7. David M Urso3,
  8. Stuart M Brierley1,2,4
  1. 1Nerve-Gut Research Laboratory, Discipline of Medicine, Faculty of Health Sciences, The University of Adelaide, Adelaide, South Australia, Australia
  2. 2Department of Gastroenterology and Hepatology, Hanson Institute, Royal Adelaide Hospital, Adelaide, South Australia, Australia
  3. 3Tioga Pharmaceuticals Inc., San Diego, California, USA
  4. 4Discipline of Physiology, Faculty of Health Sciences, The University of Adelaide, Adelaide, South Australia, Australia
  1. Correspondence to Dr Stuart M Brierley, Nerve-Gut Research Laboratory, Level 1 Hanson Institute, Frome Road, Adelaide, South Australia 5000, Australia; stuart.brierley{at}adelaide.edu.au

Statistics from Altmetric.com

In a recent article in Gut, Hughes et al1 identified distinct patterns of immune dysfunction in IBS patients compared with healthy subjects. In particular, they showed that peripheral blood mononuclear cell (PBMC) supernatants from healthy subjects inhibited colonic afferents in a μ-opioid receptor (MOR)-mediated manner. These findings correlated with β-endorphin from T lymphocytes providing an important MOR-mediated antinociceptive influence in the healthy gut.2 Intriguingly, these inhibitory effects were lost with PBMC supernatants from constipation-predominant IBS patients suggesting a loss of MOR-mediated inhibition, coupled with increased excitatory mediators (TNF-α, IL-1β, IL-6), contributes to abdominal pain.1

We evaluated if this alteration was MOR specific or whether it extended to other members of the opioid receptor family. As clinical studies have shown varying outcomes on visceral pain perception with κ-opioid receptor (KOR) agonists,35 we postulated KOR expression and function are altered during visceral hypersensitivity. Therefore, we determined if the peripherally restricted selective KOR agonist, asimadoline, was able to modify colonic nociceptor function in health and during inflammatory and postinflammatory chronic visceral mechanical hypersensitivity (CVH).6

We performed in vitro afferent recordings from mouse splanchnic high-threshold nociceptors, which respond to focal compression and noxious stretch/distension.1 ,6 …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Neurogastroenterology
    Patrick A Hughes Andrea M Harrington Joel Castro Tobias Liebregts Birgit Adam Dallas J Grasby Nicole J Isaacs Lochana Maldeniya Chris M Martin Jenny Persson Jane M Andrews Gerald Holtmann L Ashley Blackshaw Stuart M Brierley